176 related articles for article (PubMed ID: 35784305)
21. Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.
Sandbulte MR; Gauger PC; Kitikoon P; Chen H; Perez DR; Roth JA; Vincent AL
Vaccine; 2016 Jul; 34(33):3773-9. PubMed ID: 27325350
[TBL] [Abstract][Full Text] [Related]
22. Kinetics, Longevity, and Cross-Reactivity of Antineuraminidase Antibody after Natural Infection with Influenza A Viruses.
Changsom D; Jiang L; Lerdsamran H; Iamsirithaworn S; Kitphati R; Pooruk P; Auewarakul P; Puthavathana P
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29021304
[TBL] [Abstract][Full Text] [Related]
23. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
[TBL] [Abstract][Full Text] [Related]
24. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
25. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
Walz L; Kays SK; Zimmer G; von Messling V
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
[TBL] [Abstract][Full Text] [Related]
26. Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines.
Desheva Y; Smolonogina T; Donina S; Rudenko L
Antibodies (Basel); 2020 May; 9(2):. PubMed ID: 32485797
[TBL] [Abstract][Full Text] [Related]
27. Universal Influenza Virus Neuraminidase Vaccine Elicits Protective Immune Responses against Human Seasonal and Pre-pandemic Strains.
Skarlupka AL; Bebin-Blackwell AG; Sumner SF; Ross TM
J Virol; 2021 Aug; 95(17):e0075921. PubMed ID: 34160258
[TBL] [Abstract][Full Text] [Related]
28. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
[TBL] [Abstract][Full Text] [Related]
29. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.
Powers DC; Kilbourne ED; Johansson BE
Clin Diagn Lab Immunol; 1996 Sep; 3(5):511-6. PubMed ID: 8877127
[TBL] [Abstract][Full Text] [Related]
30. Stability of neuraminidase in inactivated influenza vaccines.
Sultana I; Yang K; Getie-Kebtie M; Couzens L; Markoff L; Alterman M; Eichelberger MC
Vaccine; 2014 Apr; 32(19):2225-30. PubMed ID: 24613525
[TBL] [Abstract][Full Text] [Related]
31. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
32. Anti-neuraminidase antibodies against pandemic A/H1N1 influenza viruses in healthy and influenza-infected individuals.
Desheva Y; Sychev I; Smolonogina T; Rekstin A; Ilyushina N; Lugovtsev V; Samsonova A; Go A; Lerner A
PLoS One; 2018; 13(5):e0196771. PubMed ID: 29742168
[TBL] [Abstract][Full Text] [Related]
33. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay.
Gavrilov V; Orekov T; Alabanza C; Porika U; Jiang H; Connolly K; Pincus S
J Virol Methods; 2011 May; 173(2):364-73. PubMed ID: 21419169
[TBL] [Abstract][Full Text] [Related]
34. The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.
Kawai A; Yamamoto Y; Nogimori T; Takeshita K; Yamamoto T; Yoshioka Y
J Virol; 2021 Sep; 95(20):e0118021. PubMed ID: 34379511
[TBL] [Abstract][Full Text] [Related]
35. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.
Monto AS; Petrie JG; Cross RT; Johnson E; Liu M; Zhong W; Levine M; Katz JM; Ohmit SE
J Infect Dis; 2015 Oct; 212(8):1191-9. PubMed ID: 25858957
[TBL] [Abstract][Full Text] [Related]
36. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects.
Cate TR; Rayford Y; Niño D; Winokur P; Brady R; Belshe R; Chen W; Atmar RL; Couch RB
Vaccine; 2010 Feb; 28(9):2076-9. PubMed ID: 20044052
[TBL] [Abstract][Full Text] [Related]
37. Assay Harmonization and Use of Biological Standards To Improve the Reproducibility of the Hemagglutination Inhibition Assay: a FLUCOP Collaborative Study.
Waldock J; Zheng L; Remarque EJ; Civet A; Hu B; Jalloh SL; Cox RJ; Ho S; Hoschler K; Ollinger T; Trombetta CM; Engelhardt OG; Caillet C
mSphere; 2021 Aug; 6(4):e0056721. PubMed ID: 34319129
[TBL] [Abstract][Full Text] [Related]
38. Identification of amino acids in H9N2 influenza virus neuraminidase that are critical for the binding of two mouse monoclonal antibodies.
Wan Z; Ye J; Sang J; Shao H; Qian K; Jin W; Qin A; Wan H
Vet Microbiol; 2016 May; 187():58-63. PubMed ID: 27066709
[TBL] [Abstract][Full Text] [Related]
39. [Role of antineuraminidase antibodies in protection against influenza].
Aymard M; Gerentes L; Kessler N
Bull Acad Natl Med; 1998; 182(8):1723-36; discussion 1736-7. PubMed ID: 10188318
[TBL] [Abstract][Full Text] [Related]
40. Study of Antibodies to Influenza Neuraminidase N2.
Desheva Y; Petkova N; Smolonogina T; Donina S; Go A
Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
